Register for our free email digests:
Latest From Synlogic Inc.
IPO launches in the US hit a wall in August, but several biopharma firms recently entered the queue, adding new opportunities for investors to chase the industry's outperforming returns.
A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.
Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.
Takeda will pair five cancer candidates with different mechanisms of action with Nektar's NKTR-214 and Merck follows up its Phase III disappointment verubecestat by licensing a preclinical Alzheimer's drug from Teijin.
- Drug Discovery Tools
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Metabolic Disorders
- North America
- Company Type
- Parent & Subsidiaries
- Synlogic Inc.
- Senior Management
Jose-Carlos Gutierrez-Ramos, PhD, CEO
Todd Shegog, CFO
Paul Miller, PhD, CSO
Aoife M Brennan, MD, CMO
- Contact Info
Phone: (617) 401-9947
200 Sidney St., Ste. 320
Cambridge, MA 02139
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.